Structure Therapeutics reports 16.3% weight loss in Phase 2, receives FDA Phase 3 clearance

Filed May 7, 2026 · Period ending May 7, 2026 · ~1 min read

Key Changes

• high

  Aleniglipron achieved 16.3% placebo-adjusted weight loss (39 lbs) at 180mg and 16.0% (37 lbs) at 240mg in 44-week Phase 2 ACCESS II study, with no weight loss plateau observed.

  Exhibit 99.1 verify on EDGAR →
• high

  FDA provided positive end-of-Phase 2 feedback with clear Phase 3 guidance; company plans to initiate registrational program for chronic weight management in Q3 2026.

  Exhibit 99.1 verify on EDGAR →
• high

  Company expanded at-the-market equity offering by $150M to $400M total capacity and removed aggregate offering cap, providing unlimited flexibility for future capital raises.

  Item 8.01 verify on EDGAR →